High frequency of CYP2C19*2 carriers in PCI-treated patients initially treated with clopidogrel and switched to prasugrel therapy based on a platelet function testing guided approach
Eur Heart J
2012
33 1
315-315
Early Postoperative Inflammatory Response and Serum Concentrations after Administration of Moxifloxacin and Cefuroxime for Perioperative Antibiotic Prophylaxis in Surgery with cardiopulmonary Bypass
Infection
2012
40 1
22-23
Prognostic impact of uric acid in patients with stable coronary artery disease
Eur Heart J
2012
33 1
779-779
Antiplatelet efficacy of prasugrel in patients with high platelet reactivity on clopidogrel and a history of coronary stenting
Eur Heart J
2012
33 1
320-320
Neither moxifloxacin nor cefuroxime produces significant attenuation of inflammatory mediator release in patients exposed to cardiopulmonary bypass: a randomized controlled trial.
J Antimicrob Chemother
2012
67
1
230-3
Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo
J Exp Med
2012
209
4
819-835
Association of uric acid with mortality in patients with stable coronary artery disease.
Metabolism
2012
61
12
1780-6
No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting.
Circ Cardiovasc Interv
2012
5
1
82-8, S1-2
Prognostic value of uric acid in patients with acute coronary syndromes.
Am J Cardiol
2012
109
9
1260-5
Association of midregional proadrenomedullin with coronary artery stenoses, soft atherosclerotic plaques and coronary artery calcium.
Heart Vessels
2012
27
4
352-9